Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women

Wanpen Vongpatanasin, Meryem Tuncel, Zhongyun Wang, Debbie Arbique, Borna Mehrad, Ishwarlal Jialal

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

OBJECTIVES: We investigated whether the route of estrogen replacement therapy (ET) is the major determinant of C-reactive protein (CRP) in postmenopausal women. BACKGROUND: Recent studies demonstrated that oral ET causes a sustained increase in CRP, implicating a proinflammatory effect. Because CRP is synthesized in the liver, we hypothesized that estrogen-induced CRP elevation is related to first-pass hepatic metabolism. METHODS: In 21 postmenopausal women, we conducted a randomized, crossover, placebo-controlled study to compare the effects of transdermal versus oral ET on CRP and inflammatory cytokines. We measured CRP, interleukin (IL)-1-beta, IL-6, and tumor necrosis factor-alpha before and after eight weeks of transdermal estradiol (E2) (100 μg/day), oral conjugated estrogen (CEE) (0.625 mg/day), or placebo. Insulin-like growth factor-1 (IGF-1), a hepatic-derived anabolic peptide, was also measured. RESULTS: Transdermal E2 had no effect on CRP or IGF-1 levels. In contrast, eight weeks of oral conjugated estrogens caused a more than twofold increase in CRP and a significant reduction in IGF-1 (p < 0.01) in the same women. The magnitude of increase in CRP was inversely correlated to the decrease in IGF-1 (r = -0.49, p = 0.008). Neither transdermal E2 nor oral CEE had any effects on the plasma concentrations of cytokines that promote CRP synthesis. CONCLUSIONS: In postmenopausal women, oral but not transdermal ET increased CRP by a first-pass hepatic effect. An increase in CRP levels is accompanied by a reduction in IGF-1, an anti-inflammatory growth factor. Because CRP is a powerful predictor of an adverse prognosis in otherwise healthy postmenopausal women, the route of administration may be an important consideration in minimizing the adverse effects of ET on cardiovascular outcomes.

Original languageEnglish (US)
Pages (from-to)1358-1363
Number of pages6
JournalJournal of the American College of Cardiology
Volume41
Issue number8
DOIs
StatePublished - Apr 2003

Fingerprint

Estrogen Replacement Therapy
C-Reactive Protein
Somatomedins
Conjugated (USP) Estrogens
Liver
Placebos
Cytokines
Interleukin-1beta
Estradiol
Interleukin-6
Intercellular Signaling Peptides and Proteins
Estrogens
Anti-Inflammatory Agents

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. / Vongpatanasin, Wanpen; Tuncel, Meryem; Wang, Zhongyun; Arbique, Debbie; Mehrad, Borna; Jialal, Ishwarlal.

In: Journal of the American College of Cardiology, Vol. 41, No. 8, 04.2003, p. 1358-1363.

Research output: Contribution to journalArticle

Vongpatanasin, Wanpen ; Tuncel, Meryem ; Wang, Zhongyun ; Arbique, Debbie ; Mehrad, Borna ; Jialal, Ishwarlal. / Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. In: Journal of the American College of Cardiology. 2003 ; Vol. 41, No. 8. pp. 1358-1363.
@article{d74e4068b0474733bf660168fa3899d0,
title = "Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women",
abstract = "OBJECTIVES: We investigated whether the route of estrogen replacement therapy (ET) is the major determinant of C-reactive protein (CRP) in postmenopausal women. BACKGROUND: Recent studies demonstrated that oral ET causes a sustained increase in CRP, implicating a proinflammatory effect. Because CRP is synthesized in the liver, we hypothesized that estrogen-induced CRP elevation is related to first-pass hepatic metabolism. METHODS: In 21 postmenopausal women, we conducted a randomized, crossover, placebo-controlled study to compare the effects of transdermal versus oral ET on CRP and inflammatory cytokines. We measured CRP, interleukin (IL)-1-beta, IL-6, and tumor necrosis factor-alpha before and after eight weeks of transdermal estradiol (E2) (100 μg/day), oral conjugated estrogen (CEE) (0.625 mg/day), or placebo. Insulin-like growth factor-1 (IGF-1), a hepatic-derived anabolic peptide, was also measured. RESULTS: Transdermal E2 had no effect on CRP or IGF-1 levels. In contrast, eight weeks of oral conjugated estrogens caused a more than twofold increase in CRP and a significant reduction in IGF-1 (p < 0.01) in the same women. The magnitude of increase in CRP was inversely correlated to the decrease in IGF-1 (r = -0.49, p = 0.008). Neither transdermal E2 nor oral CEE had any effects on the plasma concentrations of cytokines that promote CRP synthesis. CONCLUSIONS: In postmenopausal women, oral but not transdermal ET increased CRP by a first-pass hepatic effect. An increase in CRP levels is accompanied by a reduction in IGF-1, an anti-inflammatory growth factor. Because CRP is a powerful predictor of an adverse prognosis in otherwise healthy postmenopausal women, the route of administration may be an important consideration in minimizing the adverse effects of ET on cardiovascular outcomes.",
author = "Wanpen Vongpatanasin and Meryem Tuncel and Zhongyun Wang and Debbie Arbique and Borna Mehrad and Ishwarlal Jialal",
year = "2003",
month = "4",
doi = "10.1016/S0735-1097(03)00156-6",
language = "English (US)",
volume = "41",
pages = "1358--1363",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women

AU - Vongpatanasin, Wanpen

AU - Tuncel, Meryem

AU - Wang, Zhongyun

AU - Arbique, Debbie

AU - Mehrad, Borna

AU - Jialal, Ishwarlal

PY - 2003/4

Y1 - 2003/4

N2 - OBJECTIVES: We investigated whether the route of estrogen replacement therapy (ET) is the major determinant of C-reactive protein (CRP) in postmenopausal women. BACKGROUND: Recent studies demonstrated that oral ET causes a sustained increase in CRP, implicating a proinflammatory effect. Because CRP is synthesized in the liver, we hypothesized that estrogen-induced CRP elevation is related to first-pass hepatic metabolism. METHODS: In 21 postmenopausal women, we conducted a randomized, crossover, placebo-controlled study to compare the effects of transdermal versus oral ET on CRP and inflammatory cytokines. We measured CRP, interleukin (IL)-1-beta, IL-6, and tumor necrosis factor-alpha before and after eight weeks of transdermal estradiol (E2) (100 μg/day), oral conjugated estrogen (CEE) (0.625 mg/day), or placebo. Insulin-like growth factor-1 (IGF-1), a hepatic-derived anabolic peptide, was also measured. RESULTS: Transdermal E2 had no effect on CRP or IGF-1 levels. In contrast, eight weeks of oral conjugated estrogens caused a more than twofold increase in CRP and a significant reduction in IGF-1 (p < 0.01) in the same women. The magnitude of increase in CRP was inversely correlated to the decrease in IGF-1 (r = -0.49, p = 0.008). Neither transdermal E2 nor oral CEE had any effects on the plasma concentrations of cytokines that promote CRP synthesis. CONCLUSIONS: In postmenopausal women, oral but not transdermal ET increased CRP by a first-pass hepatic effect. An increase in CRP levels is accompanied by a reduction in IGF-1, an anti-inflammatory growth factor. Because CRP is a powerful predictor of an adverse prognosis in otherwise healthy postmenopausal women, the route of administration may be an important consideration in minimizing the adverse effects of ET on cardiovascular outcomes.

AB - OBJECTIVES: We investigated whether the route of estrogen replacement therapy (ET) is the major determinant of C-reactive protein (CRP) in postmenopausal women. BACKGROUND: Recent studies demonstrated that oral ET causes a sustained increase in CRP, implicating a proinflammatory effect. Because CRP is synthesized in the liver, we hypothesized that estrogen-induced CRP elevation is related to first-pass hepatic metabolism. METHODS: In 21 postmenopausal women, we conducted a randomized, crossover, placebo-controlled study to compare the effects of transdermal versus oral ET on CRP and inflammatory cytokines. We measured CRP, interleukin (IL)-1-beta, IL-6, and tumor necrosis factor-alpha before and after eight weeks of transdermal estradiol (E2) (100 μg/day), oral conjugated estrogen (CEE) (0.625 mg/day), or placebo. Insulin-like growth factor-1 (IGF-1), a hepatic-derived anabolic peptide, was also measured. RESULTS: Transdermal E2 had no effect on CRP or IGF-1 levels. In contrast, eight weeks of oral conjugated estrogens caused a more than twofold increase in CRP and a significant reduction in IGF-1 (p < 0.01) in the same women. The magnitude of increase in CRP was inversely correlated to the decrease in IGF-1 (r = -0.49, p = 0.008). Neither transdermal E2 nor oral CEE had any effects on the plasma concentrations of cytokines that promote CRP synthesis. CONCLUSIONS: In postmenopausal women, oral but not transdermal ET increased CRP by a first-pass hepatic effect. An increase in CRP levels is accompanied by a reduction in IGF-1, an anti-inflammatory growth factor. Because CRP is a powerful predictor of an adverse prognosis in otherwise healthy postmenopausal women, the route of administration may be an important consideration in minimizing the adverse effects of ET on cardiovascular outcomes.

UR - http://www.scopus.com/inward/record.url?scp=0037394565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037394565&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(03)00156-6

DO - 10.1016/S0735-1097(03)00156-6

M3 - Article

C2 - 12706932

AN - SCOPUS:0037394565

VL - 41

SP - 1358

EP - 1363

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 8

ER -